By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the neoantigen repertoire in cancer.
Location: United States, Ohio, Oxford
Member count: 11-50
Total raised: $61.863754M
Founded date: 2018
Investors 2
| Date | Name | Website |
| 01.02.2023 | British Pa... | britishpat... |
| - | Canaan Par... | canaan.com |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 27.01.2023 | Series B | $49M | - | finsmes.co... |
| 11.02.2019 | Series A | $12.863754... | Andera Par... | anderapart... |
Mentions in press and media 5
| Date | Title | Description | Category | Author | Source |
| 27.01.2023 | British Pa... | 26 January 2023: British Patie... | - | - | britishpat... |
| 26.01.2023 | Grey Wolf ... | Grey Wolf Therapeutics, an Oxf... | UK | - | finsmes.co... |
| 08.11.2019 | Cambridge ... | Cambridge companies recognised... | - | - | cambridgen... |
| 11.02.2019 | Grey Wolf ... | Grey Wolf Therapeutics compl... | - Press re... | - | anderapart... |
| - | Grey Wolf ... | “By targeting the ERAP proteas... | - | - | fastfounde... |